Search Result

Results for "

activity of BACE-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Beta-secretase (24) Acyltransferase (2) Adrenergic Receptor (2) Akt (3) Amyloid-β (5) Antibiotic (2) Apoptosis (4) Autophagy (2) Bacterial (2) Bcl-2 Family (2) Cholinesterase (ChE) (15) COX (4) Drug Isomer (1) Endogenous Metabolite (1) ERK (2) Fluorescent Dye (1) GABA Receptor (2) GSK-3 (1) Interleukin Related (2) JNK (2) Monoamine Oxidase (2) mTOR (2) NF-κB (4) NO Synthase (2) Opioid Receptor (1) p38 MAPK (2) PERK (2) Phosphodiesterase (PDE) (1) PI3K (2) Prostaglandin Receptor (2) Reactive Oxygen Species (ROS) (1) Reference Standards (4) ROS Kinase (2) TNF Receptor (2)
By Research Areas:	Cancer (7) Infection (2) Inflammation/Immunology (7) Metabolic Disease (2) Neurological Disease (31)

By Targets:

Beta-secretase (24)

Acyltransferase (2)

Adrenergic Receptor (2)

Akt (3)

Amyloid-β (5)

Antibiotic (2)

Apoptosis (4)

Autophagy (2)

Bacterial (2)

Bcl-2 Family (2)

Cholinesterase (ChE) (15)

COX (4)

Drug Isomer (1)

Endogenous Metabolite (1)

ERK (2)

Fluorescent Dye (1)

GABA Receptor (2)

GSK-3 (1)

Interleukin Related (2)

JNK (2)

Monoamine Oxidase (2)

mTOR (2)

NF-κB (4)

NO Synthase (2)

Opioid Receptor (1)

p38 MAPK (2)

PERK (2)

Phosphodiesterase (PDE) (1)

PI3K (2)

Prostaglandin Receptor (2)

Reactive Oxygen Species (ROS) (1)

Reference Standards (4)

ROS Kinase (2)

TNF Receptor (2)

By Research Areas:

Cancer (7)

Infection (2)

Inflammation/Immunology (7)

Metabolic Disease (2)

Neurological Disease (31)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Targets Recommended: Beta-secretase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15908

BCA 5+ Cited Publications Disodium bicinchoninate	Beta-secretase	Neurological Disease Cancer
BCA (Disodium bicinchoninate) is an orally active and non-competitive Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC₅₀ value of 28 µM, a K_i value of 43 µM. BCA shows anticancer activity. BCA has the potential for the research of Alzheimer's disease (AD) .

HY-N0226A

Epiberberine chloride 4 Publications Verification	Cholinesterase (ChE) Beta-secretase Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease
Epiberberine chloride is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive *BACE1* inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine chloride has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and may protect against Alzheimer disease . Epiberberine chloride inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberine has the potential effect in the research of diabetic disease .

HY-N0631

Cornuside Maximum Cited Publications 6 Publications Verification	p38 MAPK NF-κB JNK Cholinesterase (ChE) Acyltransferase NO Synthase Interleukin Related TNF Receptor Prostaglandin Receptor ERK COX	Neurological Disease Inflammation/Immunology
Cornuside is an iridoid glycoside with anti-allergic, anti-inflammatory, and neuroprotective activities. Cornuside exerts anti-allergic activity by downregulating the p38 MAPK, JNK, and NF-κB signaling pathways, and inhibits IgE-mediated histamine release from mast cells. Cornuside improves cognitive impairment in mice by inhibiting *BACE1* activity (IC₅₀ = 55.84 μg/mL) and enhancing ChAT activity. Cornuside inhibits LPS (HY-D1056)-induced inflammatory mediators, including iNOS, COX-2, PGE2, TNF-α, IL-6, and IL-1β, by suppressing NF-κB activation .

HY-N0226

Epiberberine	Cholinesterase (ChE) Beta-secretase	Neurological Disease Metabolic Disease
Epiberberine is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive *BACE1* inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and can be used for the research of Alzheimer disease . Epiberberine inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberinecan be used for the research of diabetic disease .

HY-N0231

Bavachalcone 2 Publications Verification Broussochalcone B	Bacterial Antibiotic NF-κB PERK Akt Autophagy Apoptosis	Infection Neurological Disease Inflammation/Immunology Cancer
Bavachalcone is a potent inducer of apoptosis. Bavachalcone exerts anticancer activity by promoting autophagy and apoptosis in HepG2 cells. Bavachalcone acts as an anti-neuroinflammatory and antidepressant through the NF-κB pathway. Bavachalcone inhibits osteoclasts by interfering with ERK and Akt signaling pathways and the expression of c-Fos and NFATc1. Bavachalcone exhibits a significant inhibitory effect on baculovirus-expressed BACE-1 in vitro .

HY-N1255

Scoulerine (-)-Scoulerine; Discretamine	Bcl-2 Family Apoptosis mTOR GABA Receptor PI3K Adrenergic Receptor Beta-secretase Akt	Cancer
Scoulerine ((-)-Scoulerine; Discretamine) hydrochloride is a multi-target inhibitor with anti-tumor and antioxidant activities. Scoulerine mainly targets the PI3K/Akt/mTOR signaling axis and α1D-adrenergic receptor, disrupts microtubule structure, and induces cell cycle arrest and apoptosis. Scoulerine effectively inhibits mitochondrial dehydrogenase activity, targets GABA receptors and *BACE1, and suppresses the proliferation, migration, invasion, epithelial-mesenchymal transition and stem cell properties of cancer cells. Scoulerine also exhibits multiple pharmacological activities* including anti-Plasmodium falciparum, antibacterial, antiemetic and antitussive effects, and regulates endoplasmic reticulum stress and mitochondrial function (modulates Bax, Bcl-2 and cytochrome c). Scoulerine is applicable to research related to leukemia, ovarian cancer, and colorectal cancer .

HY-N1280

Semilicoisoflavone B	Amyloid-β	Neurological Disease
Semilicoisoflavone B, an isoflavone, mainly derived from Glycyrrhiza uralensis Fisch.. Semilicoisoflavone B reduces amyloid β (Aβ) secretion by inhibiting β-secretase-1 (BACE1) expression and activity. Semilicoisoflavone B decreases BACE1 expression mainly through increasing PPARγ expression and inhibiting STAT3 phosphorylation .

HY-N2215

Aloeresin D	Beta-secretase	Neurological Disease
Aloeresin D is a chromone glycoside isolated from Aloe vera, inhibits β-Secretase (BACE1) activity, with an IC₅₀ of 39 μM .

HY-P4920

Mca-SEVNLDAEFK(Dnp)-NH2	Fluorescent Dye	Others
Mca-SEVNLDAEFK(Dnp)-NH2 contains a highly fluorescent 7-methoxycoumarin group that is efficiently quenched by resonance energy transfer to the 2,4-dinitrophenyl group. It can be used to measure the activities of peptidases that are capable of cleaving an amide bond between the fluorescent group and the quencher group, causing an increase in fluorescence, such as can be used to measure the activity of BACE-1 .

HY-N2284

Sophoflavescenol	Cholinesterase (ChE) Beta-secretase Phosphodiesterase (PDE)	Cancer
Sophoflavescenol is a prenylated flavonol, which shows great inhibitory activity with IC₅₀ of 0.013 μM against Phosphodiesterase 5 (PDE5), and also inhibits RLAR, HRAR, AGE, BACE1, AChE and BChE with IC₅₀s of 0.30 μM, 0.17 μM, 17.89 μg/mL, 10.98 μM, 8.37 μM and 8.21 μM, respectively.

HY-108966

Kushenol C	Beta-secretase	Inflammation/Immunology
Kushenol C, isolated from the roots of Sophora flavescens, shows anti-Inflammatory and anti-oxidative stress activities. Kushenol C inhibits BACE1 (β-site APP cleaving enzyme 1) with an IC₅₀ of 5.45 µM .

HY-N7887

Cassiaside	Beta-secretase	Neurological Disease Inflammation/Immunology
Cassiaside is a naphthopyrone glucoside, shows mixed-type inhibition against *BACE1* (IC₅₀=4.45 μM; K_i=9.85 μM). Cassiaside possesses potential anti- Alzheimer's disease (AD) activity .

HY-149340

PD07	Cholinesterase (ChE)	Neurological Disease
PD07 is an orally active AChE inhibitor (IC₅₀: 0.29 μM for hAChE). PD07 also inhibits ChEs, BACE1 (IC₅₀: 13.42 μM), and Aβ_1–42 aggregation in in vitro. PD07 is an antioxidant, and shows DPPH inhibitory activity (IC₅₀: 26.46 μM). PD07 improves memory and cognition in Scopolamine (HY-N0296)-induced amnesia rats. PD07 can be used for research of Alzheimer’s disease .

HY-175661

SRI-22136	Opioid Receptor Beta-secretase	Neurological Disease
SRI-22136 is a Delta Opioid Receptor (DOR) antagonist that can cross blood-brain barrier with a IC₅₀ of 0.42 nM. SRI-22136 does not have agonistic activity but antagonistic activity against DOR, MOR (IC₅₀ = 370 nM), KOR (IC₅₀ = 54 nM) and can avoid addiction/aversion effects. SRI-22136 can effectively inhibit the *BACE1* activity induced by DADLE (a DOR agonist) (HY-105343) (IC₅₀ = 120 nM). SRI-22136 prevents completely Alzheimer’s-like pathology in mouse model. SRI-22136 can used for the study of Alzheimer’s disease .

HY-P3426

BACE1-IN-10	Beta-secretase	Cancer
BACE1-IN-10 is a potent *BACE1* Inhibitor. BACE1-IN-10 shows sub-micromolar activity against recombinant BACE1 (rBACE1) .

HY-151348

BACE1-IN-11	Beta-secretase	Neurological Disease
BACE1-IN-11 is a *BACE1* inhibitor. BACE1-IN-11 has the BACE1 inhibitory activity with an IC₅₀ value of 72 μM. BACE1-IN-11 can be used for the research of Alzheimer’s disease (AD) .

HY-147851

BACE1-IN-12	Beta-secretase	Neurological Disease
BACE1-IN-12 (compound 7g) is a potent and BBB-penetrated *BACE1* inhibitor, with an IC₅₀ of 8.9 µM. BACE1-IN-12 shows selective BuChE (butyrylcholinesterase) inhibitory activity with an IC₅₀ of 3.2 µM. BACE1-IN-12 shows effective antioxidant effect with an IC₅₀ of 10.2 μM (DPPH). BACE1-IN-12 might be served as a potential anti-Alzheimer agent .

HY-173226

BACE1-IN-15	Beta-secretase	Neurological Disease
BACE1-IN-15 (Compound 72) is a selective inhibitor of beta-site amyloid precursor protein cleaving enzyme 1 (BACE-1) with oral activity and the ability to penetrate the blood-brain barrier. Its IC₅₀ value is 121.65 nM (the IC₅₀ value for BACE-2 is 480.92 nM). BACE1-IN-15 can be used in the research of the Alzheimer's disease field

HY-151260

AChE/BACE1/GSK3β-IN-1	Beta-secretase Cholinesterase (ChE) GSK-3	Neurological Disease
AChE/BACE1/GSK3β-IN-1 is an orally active triple inhibitor of *AChE/BACE1/GSK3β. AChE/BACE1/GSK3β-IN-1 has effective inhibitory activity* against AChE, BACE1 and GSK3β with IC₅₀ values of 1.0 μM, 20 μM and 15 μM, respectively. AChE/BACE1/GSK3β-IN-1 has good blood-brain barrier penetrability, suitable bioavailability. AChE/BACE1/GSK3β-IN-1 can be used for the research of Alzheimer's disease (AD) .

HY-P4899

β-Secretase substrate VI, fluorogenic RE(EDANS)EVNLDAEFK(DABCYL)R	Beta-secretase	Neurological Disease
β-Secretase substrate VI, fluorogenic is an EDANS and DABCYL double-labeled peptide，serves as a fluorescent substrate for BACE1(Em=360nm，Ex=528nm). β-Secretase substrate VI, fluorogenic can be used for BACE1 activity measurement and the enzyme activity level is directly proportional to the fluorescence reaction .

HY-147658

AChE/BChE/BACE-1-IN-1	Cholinesterase (ChE) Beta-secretase ROS Kinase	Neurological Disease
AChE/BChE/BACE-1-IN-1 (Compound 4k) is an orally active inhibitor of AChE, BChE, and *BACE-1* with IC₅₀ values of 0.058, 0.082 and 0.115 μM against hAChE, hBChE and hBACE-1, respectively. AChE/BChE/BACE-1-IN-1 shows considerable PAS-AChE binding capability, excellent brain permeation, potential disassembly of Aβ aggregates, and neuroprotective activity against Aβ-induced stress. AChE/BChE/BACE-1-IN-1 has remarkable antioxidant potential .

HY-147659

AChE/BChE/BACE-1-IN-2	Cholinesterase (ChE) Beta-secretase ROS Kinase	Neurological Disease
AChE/BChE/BACE-1-IN-2 (Compound 4o) is an orally active inhibitor of AChE, BChE, and *BACE-1* with IC₅₀ values of 0.069, 0.127 and 0.097 μM against hAChE, hBChE and hBACE-1, respectively. AChE/BChE/BACE-1-IN-2 shows considerable PAS-AChE binding capability, excellent brain permeation, potential disassembly of Aβ aggregates, and neuroprotective activity against Aβ-induced stress. AChE/BChE/BACE-1-IN-2 has remarkable antioxidant potential .

HY-N2215R

Aloeresin D (Standard)	Reference Standards Beta-secretase	Neurological Disease
Aloeresin D (Standard) is the analytical standard of Aloeresin D. This product is intended for research and analytical applications. Aloeresin D is a chromone glycoside isolated from Aloe vera, inhibits β-Secretase (BACE1) activity, with an IC₅₀ of 39 μM .

HY-W750970

2-Acetoxyacorenone	Beta-secretase Cholinesterase (ChE)	Neurological Disease
2-Acetoxyacorenone (compound 8) is a sesquiterpenoid, which can be isolated from the rhizome of Acorus tatarinowii. 2-Acetoxyacorenone has potent AChE and *β-BACE1* inhibitory activity and can be used in the study of Alzheimer's disease .

HY-155304

BuChE-IN-8	Cholinesterase (ChE)	Neurological Disease
BuChE-IN-8 (compound 19c) is a butyrylcholinesterase (BuChE) inhibitor with an IC₅₀ of 559 nM. BuChE-IN-8 possesses human β-secretase (BACE1) and Aβ40 aggregation inhibitory activities. BuChE-IN-8 has significant antiamnesic properties .

HY-N0231R

Bavachalcone (Standard) Broussochalcone B (Standard)	Reference Standards Bacterial Antibiotic NF-κB PERK Apoptosis Autophagy	Infection Neurological Disease Inflammation/Immunology Cancer
Bavachalcone (Standard) is the analytical standard of Bavachalcone. This product is intended for research and analytical applications. Bavachalcone is a potent inducer of apoptosis. Bavachalcone exerts anticancer activity by promoting autophagy and apoptosis in HepG2 cells. Bavachalcone acts as an anti-neuroinflammatory and antidepressant through the NF-κB pathway. Bavachalcone inhibits osteoclasts by interfering with ERK and Akt signaling pathways and the expression of c-Fos and NFATc1. Bavachalcone exhibits a significant inhibitory effect on baculovirus-expressed BACE-1 in vitro .

HY-157527

hAChE-IN-7	Cholinesterase (ChE) Beta-secretase	Neurological Disease
hAChE-IN-7 (compound 5s) is a mixed inhibitor affecting both the catalytic active site (CAS) and peripheral anionic site (PAS) of hAChE. hAChE-IN-7 displays the balanced inhibitory effect on hAChE (IC₅₀=69.8 nM) and hBuChE (IC₅₀=68.0 nM), and exhibits inhibitory activity against β-secretase-1 (BACE-1) (IC₅₀=3.6 μM). hAChE-IN-7 has the potential for Alzheimer's disease (AD) research .

HY-155085

hAChE-IN-3	Monoamine Oxidase Amyloid-β Cholinesterase (ChE)	Neurological Disease
hAChE-IN-3 (compounds 5c) is a potent and blood-brain barrier permeable AChE, BuChE， MAO-B-IN-1 and *BACE-1* inhibitor, with IC₅₀ values of 0.44, 0.08, 5.15 and 0.38 μM, respectively. hAChE-IN-3 has antioxidant activity and metal chelating ability. In addition, hAChE-IN-3 can bind to peripheral anion sites, and affect β amyloid and reduce Alzheimer's-associated neurodegeneration. hAChE-IN-3 has the potential for the research of Alzheimer's disease .

HY-129133

cis-Miyabenol C	Drug Isomer	Others
cis-Miyabenol C is an isomer of the resveratrol trimer Miyabenol C, which can be isolated from grape herbs. Miyabenol C is an inhibitor of β-amyloid (Aβ) and amyloid β precursor protein (APP) in Alzheimer's disease model mice, and inhibit β-secretase activity without changing the protein level of β-secretase BACE1 .

HY-N0249R

Saikosaponin C (Standard)	Reference Standards Amyloid-β	Neurological Disease
Saikosaponin C (Standard) is the analytical standard of Saikosaponin C. This product is intended for research and analytical applications. Saikosaponin C is a bioactive component found in radix bupleuri, targets amyloid beta and tau in Alzheimer's disease. Saikosaponin C inhibits the secretion of both Aβ1-40 and Aβ1-42, and suppresses abnormal tau phosphorylation, but shows no effect on BACE1 activity and expression .

HY-115973

AChE-IN-11	Cholinesterase (ChE)	Neurological Disease
AChE-IN-11 (compound 5C) is a triple inhibitor targeting *AChE/MAO-B/BACE1* (IC₅₀=7.9 μM, 9.9 μM, 8.3 μM, respectively) and a selective metal ion chelators. AChE-IN-11 exhibits mixed AChE inhibitory effects, binding to both CAS and PAS of AChE. AChE-IN-11 also exhibits good antioxidant activity (ORAC=2.5 eq) and potential neuroprotective effects in Alzheimer's disease .

HY-N0631R

Cornuside (Standard)	Reference Standards Prostaglandin Receptor ERK p38 MAPK Acyltransferase TNF Receptor COX Cholinesterase (ChE) Interleukin Related JNK NO Synthase NF-κB	Neurological Disease Inflammation/Immunology
Cornuside (Standard) is the analytical standard of Cornuside (HY-N0631). This product is intended for research and analytical applications. Cornuside is an iridoid glycoside with anti-allergic, anti-inflammatory, and neuroprotective activities. Cornuside exerts anti-allergic activity by downregulating the p38 MAPK, JNK, and NF-κB signaling pathways, and inhibits IgE-mediated histamine release from mast cells. Cornuside improves cognitive impairment in mice by inhibiting *BACE1* activity (IC₅₀ = 55.84 μg/mL) and enhancing ChAT activity. Cornuside inhibits LPS (HY-D1056)-induced inflammatory mediators, including iNOS, COX-2, PGE2, TNF-α, IL-6, and IL-1β, by suppressing NF-κB activation.

HY-N18261

8-Geranyloxy-5-methoxypsoralen	Beta-secretase	Neurological Disease
8-geranyloxy-5-methoxypsoralen is a *BACE1* inhibitor with an IC₅₀ of 11.1 μM. 8-geranyloxy-5-methoxypsoralen potently inhibits BACE1 activity. 8-Geranyloxy-5-methoxypsoralen can be used for the research of Alzheimer's disease .

HY-116580

AZD-3289	Endogenous Metabolite	Neurological Disease
AZD-3289 is a potent BACE1 inhibitor with potential Alzheimer's disease inhibitory activity. The application of AZD-3289 is intended to slow the pathological progression of Alzheimer's disease by inhibiting the production of β-amyloid protein. The development of AZD-3289 responds to the need to reduce neurodegenerative changes associated with Alzheimer's disease. As a BACE1 inhibitor, AZD-3289 can effectively reduce the accumulation of β-amyloid peptide in the brain, which may improve cognitive function .

HY-125405

AZ3971	Beta-secretase Amyloid-β	Neurological Disease
AZ3971 is an orally active, blood-brain barrier permeable *BACE1* inhibitor that does not affect the activity of γ-secretase. AZ3971 reduces the production of Aβ. AZ3971 can be used for the research of Alzheimer's disease .

HY-W347202

N-Caffeoyl serotonin	COX	Neurological Disease Inflammation/Immunology
N-Caffeoyl serotonin is a COX-2 inhibitor, with IC₅₀ and Kᵢ values of 42.5 μM and 65.5 μM against COX-2, respectively. N-Caffeoyl serotonin exhibits weak inhibitory activity against BACE1, with an IC₅₀ > 400 μM. N-Caffeoyl serotonin has free radical scavenging activity. N-Caffeoyl serotonin can be used in the research of allergic diseases and Alzheimer's disease .

HY-182786

MAO-B-IN-56	Cholinesterase (ChE) Monoamine Oxidase Beta-secretase COX Amyloid-β	Neurological Disease
MAO-B-IN-56 is a multi-target-directed ligand with AChE, BChE, MAO-B, and *BACE1* inhibitory activity, with IC₅₀ values of 0.35 μM, 3.22 μM, 0.14 μM, and 3.85 μM respectively, and shows selectivity for AChE over BChE and MAO-B over MAO-A.MAO-B-IN-56 reduces amyloid-beta production, reduces paw edema, improves spatial memory, and enhances Alzheimer's disease hallmarks and associated histopathological alterations.MAO-B-IN-56 can be used for the research of alzheimer's disease .

HY-N1255A

Scoulerine hydrochloride (-)-Scoulerine hydrochloride; Discretamine hydrochloride	Apoptosis PI3K Akt mTOR Adrenergic Receptor GABA Receptor Beta-secretase Bcl-2 Family	Cancer
Scoulerine ((-)-Scoulerine; Discretamine) hydrochloride is a multi-target inhibitor with anti-tumor and antioxidant activities. Scoulerine hydrochloride mainly targets the PI3K/Akt/mTOR signaling axis and α1D-adrenergic receptor, disrupts microtubule structure, and induces cell cycle arrest and apoptosis. Scoulerine hydrochloride effectively inhibits mitochondrial dehydrogenase activity, targets GABA receptors and *BACE1, and suppresses the proliferation, migration, invasion, epithelial-mesenchymal transition and stem cell properties of cancer cells. Scoulerine hydrochloride also exhibits multiple pharmacological activities* including anti-Plasmodium falciparum, antibacterial, antiemetic and antitussive effects, and regulates endoplasmic reticulum stress and mitochondrial function (modulates Bax, Bcl-2 and cytochrome c). Scoulerine hydrochloride is applicable to research related to leukemia, ovarian cancer, and colorectal cancer .

Cat. No.	Product Name	Type